La Jolla pharma still rocking on today in late afternoon trading up up 41% [over $1.71 per share] to $5.84 on news of positive clinical data from it's Lupus drug Riquent.
Rock on!
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Focal adhesions are where the cell attaches to it's substrate, whether a blood vessel or the basement membrane. The focal contacts are shown in green, the connections to other cells in blue and actin in red.
A Scientific Interpretation of Stock and Clinical Trial Data that's easy to understand
Check out Whatisthatdrug.com--new posts daily on drugs advertised in current media
Focal Adhesions: How cells crawl along
Focal adhesions are where the cell attaches to it's substrate, whether a blood vessel or the basement membrane. The focal contacts are shown in green, the connections to other cells in blue and actin in red.
About Me
- Science Food Logic
- I have wet bench research experience in pharmacology, biochemistry and cell biology. Further, I have clinical research experience in ophthalmology, pathology and immunology. I am employed full time as a research scientist in the pharmaceutical industry. In my off time, I enjoy creating fine dining dishes as well as 20 minute meals that taste like fine dining. I like to teach both professionally and in the kitchen.
Blog Archive
-
▼
2007
(78)
-
▼
March
(18)
- Very Cool! Vical gets conditional approval for Can...
- Charles River Forms China Joint Venture
- Gilead Jumps up 2 dollars a share on Outlook
- Acadia Schizophrenia Drug Meets Endpoint
- Hollis-Eden stock roars up 29%
- Biotech News Friday: Trimeris stock plunges on CEO...
- FDA Approves GlaxoSmithKline's TYKERB(R) in combin...
- Affymetrix Rises on Illumina Verdict
- Update: La Jolla Pharma still cruising
- In my backyard: La Jolla Pharma Shares Surge on data
- Tercica Shares Surge on Settlement
- CV Therapeutics Drug Fails Study
- BioCryst stock jumps on news of bird flu
- Aftermarket News: InterMune Discontinues Phase 3 I...
- Memory Pharma Drops on Failed Study
- OncoGenex Delays IPO AGAIN
- Biotechnology Mid-Day trading Report
- After this mornings meltdown, some good news: Alp...
-
▼
March
(18)
No comments:
Post a Comment